Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

457
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
457

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Qualitative Analysis of Telemedicine Use Among Urban and Rural Patients With Urologic Malignancies.

JU open plus·2026
Same author

Cost-effectiveness of fecal immunochemical testing for colorectal cancer in Mexico City: A microsimulation modeling study.

Journal of medical screening·2026
Same author

A Tutorial on Discrete Event Simulation Models Using a Cost-Effectiveness Analysis Example in R.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

A Microsimulation-Based Approach for Mitigating Societal Bias in Chronic Kidney Disease Data.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

Cost-Effectiveness of the I'm Ready HIV Self-Testing Programme Among High-Risk Populations in Canada.

Journal of the International AIDS Society·2026
Same author

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer.

Breast cancer research and treatment·2026
Same journal

Retraction: Menstrual Factors, Reproductive History and Liver Cancer Risk: Findings from a Prospective Cohort Study in Chinese Women.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Optimizing the Uptake and Completion of the Cervical Cancer Screening Continuum: Opportunity Knocks, Including at Home.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Sex Differences in Cancer Stage at Diagnosis of Nonreproductive Solid Organ Tumors in the United States, 2015 to 2022.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Reply.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Evaluation of the 4Kscore in EPIC: Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Dietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohort.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

201

Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study.

Praveen Kumar1,2, Jennifer Ruhl3, Tanvi V Chiddarwar4

  • 1Department of Health Policy and Management, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|July 11, 2025
PubMed
Summary
This summary is machine-generated.

The revised harmonized staging variable for bladder cancer provides smoother incidence trends and better data completeness. This new system reveals previously hidden patterns in epidemiologic outcomes, improving cancer registry analysis.

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.4K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.9K

Related Experiment Videos

Last Updated: Sep 16, 2025

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

201
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.4K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.9K

Area of Science:

  • Epidemiology
  • Cancer Registry Science
  • Oncology

Background:

  • Disease definition coding changes impact bladder cancer registry trends.
  • The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable for improved long-term trend analysis.
  • This study evaluates bladder cancer incidence trends using the harmonized staging variable.

Purpose of the Study:

  • To analyze bladder cancer incidence trends using the SEER harmonized staging variable.
  • To compare trends derived from the harmonized staging variable against historical staging variables.
  • To assess the impact of staging variable revisions on the clarity and continuity of epidemiologic data.

Main Methods:

  • Utilized SEER 12 registry data for bladder cancer cases diagnosed between 1992 and 2019.
  • Compared incidence trends using the harmonized staging variable versus original staging variables (SEER modified AJCC 3rd ed., Derived AJCC 6th ed., Derived SEER Combined, Derived EOD 2018).
  • Employed joinpoint regression analysis to identify and analyze trend changes.

Main Results:

  • The harmonized staging system significantly reduced missing lymph node and metastasis stage data.
  • Trends varied between staging systems, with the harmonized system exhibiting fewer discontinuities.
  • A consistent 4% annual decrease in Tis (carcinoma in situ) incidence was observed with the harmonized staging system since 1992, unlike trends with original systems.

Conclusions:

  • The revised harmonized staging variable reveals consistent decreases in Tis incidence and smoother temporal trends.
  • The harmonized staging system enhances data availability and reduces trend discontinuities compared to original variables.
  • Revised staging variables offer a more nuanced understanding of epidemiological temporal trends in bladder cancer.